![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Pfizer Global Research and Development, Groton Laboratories, Groton, Connecticut
Unbound fractions in mouse brain and plasma were determined for 31 structurally diverse central nervous system (CNS) drugs and two active metabolites. Three comparisons were made between in vitro binding and in vivo exposure data, namely: 1) mouse brain-to-plasma exposure versus unbound plasma-to-unbound brain fraction ratio (fuplasma/fubrain), 2) cerebrospinal fluid-to-brain exposure versus unbound brain fraction (fubrain), and 3) cerebrospinal fluid-to-plasma exposure versus unbound plasma fraction (fuplasma). Unbound fraction data were within 3-fold of in vivo exposure ratios for the majority of the drugs examined (i.e., 22 of 33), indicating a predominately free equilibrium across the blood-brain and blood-CSF barriers. Some degree of distributional impairment at either the blood-CSF or the blood-brain barrier was indicated for 8 of the 11 remaining drugs (i.e., carbamazepine, midazolam, phenytoin, sulpiride, thiopental, risperidone, 9-hydroxyrisperidone, and zolpidem). In several cases, the indicated distributional impairment is consistent with other independent literature reports for these drugs. Through the use of this approach, it appears that most CNS-active agents freely equilibrate across the blood-brain and blood-CSF barriers such that unbound drug concentrations in brain approximate those in the plasma. However, these results also support the intuitive concept that distributional impairment does not necessarily preclude CNS activity.
This article has been cited by other articles:
|
|
 |
|
  X. Liu, O. Vilenski, J. Kwan, S. Apparsundaram, and R. Weikert Unbound Brain Concentration Determines Receptor Occupancy: A Correlation of Drug Concentration and Brain Serotonin and Dopamine Reuptake Transporter Occupancy for Eighteen Compounds in Rats Drug Metab. Dispos., July 1, 2009; 37(7): 1548 - 1556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhou, K. Schmidt, F. R. Nelson, V. Zelesky, M. D. Troutman, and B. Feng The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice Drug Metab. Dispos., May 1, 2009; 37(5): 946 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Liu, K. Van Natta, H. Yeo, O. Vilenski, P. E. Weller, P. D. Worboys, and M. Monshouwer Unbound Drug Concentration in Brain Homogenate and Cerebral Spinal Fluid at Steady State as a Surrogate for Unbound Concentration in Brain Interstitial Fluid Drug Metab. Dispos., April 1, 2009; 37(4): 787 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Kielbasa, J. C. Kalvass, and R. Stratford Microdialysis Evaluation of Atomoxetine Brain Penetration and Central Nervous System Pharmacokinetics in Rats Drug Metab. Dispos., January 1, 2009; 37(1): 137 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. E. Savoy, M. A. Ashton, M. W. Miller, F. M. Nedza, D. K. Spracklin, M. H. Hawthorn, H. Rollema, F. F. Matos, and E. Hajos-Korcsok Differential Effects of Various Typical and Atypical Antipsychotics on Plasma Glucose and Insulin Levels in the Mouse: Evidence for the Involvement of Sympathetic Regulation Schizophr Bull, August 14, 2008; (2008) sbn104v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Liu, C. Chen, and B. J. Smith Progress in Brain Penetration Evaluation in Drug Discovery and Development J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 349 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Venkatakrishnan, E. Tseng, F. R. Nelson, H. Rollema, J. L. French, I. V. Kaplan, W. E. Horner, and M. A. Gibbs Central Nervous System Pharmacokinetics of the Mdr1 P-Glycoprotein Substrate CP-615,003: Intersite Differences and Implications for Human Receptor Occupancy Projections from Cerebrospinal Fluid Exposures Drug Metab. Dispos., August 1, 2007; 35(8): 1341 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Kalvass, T. S. Maurer, and G. M. Pollack Use of Plasma and Brain Unbound Fractions to Assess the Extent of Brain Distribution of 34 Drugs: Comparison of Unbound Concentration Ratios to in Vivo P-Glycoprotein Efflux Ratios Drug Metab. Dispos., April 1, 2007; 35(4): 660 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Zamek-Gliszczynski, K.-i. Nezasa, X. Tian, J. C. Kalvass, N. J. Patel, T. J. Raub, and K. L. R. Brouwer The Important Role of Bcrp (Abcg2) in the Biliary Excretion of Sulfate and Glucuronide Metabolites of Acetaminophen, 4-Methylumbelliferone, and Harmol in Mice Mol. Pharmacol., December 1, 2006; 70(6): 2127 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Liu, B. J. Smith, C. Chen, E. Callegari, S. L. Becker, X. Chen, J. Cianfrogna, A. C. Doran, S. D. Doran, J. P. Gibbs, et al. Evaluation of Cerebrospinal Fluid Concentration and Plasma Free Concentration As a Surrogate Measurement for Brain Free Concentration Drug Metab. Dispos., September 1, 2006; 34(9): 1443 - 1447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Becker and X. Liu EVALUATION OF THE UTILITY OF BRAIN SLICE METHODS TO STUDY BRAIN PENETRATION Drug Metab. Dispos., May 1, 2006; 34(5): 855 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Summerfield, A. J. Stevens, L. Cutler, M. del Carmen Osuna, B. Hammond, S.-P. Tang, A. Hersey, D. J. Spalding, and P. Jeffrey Improving the in Vitro Prediction of in Vivo Central Nervous System Penetration: Integrating Permeability, P-glycoprotein Efflux, and Free Fractions in Blood and Brain J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1282 - 1290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gupta, P. Chatelain, R. Massingham, E. N. Jonsson, and M. Hammarlund-Udenaes BRAIN DISTRIBUTION OF CETIRIZINE ENANTIOMERS: COMPARISON OF THREE DIFFERENT TISSUE-TO-PLASMA PARTITION COEFFICIENTS: Kp, Kp,u, AND Kp,uu Drug Metab. Dispos., February 1, 2006; 34(2): 318 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Liu, B. J. Smith, C. Chen, E. Callegari, S. L. Becker, X. Chen, J. Cianfrogna, A. C. Doran, S. D. Doran, J. P. Gibbs, et al. Use of a Physiologically Based Pharmacokinetic Model to Study the Time to Reach Brain Equilibrium: An Experimental Analysis of the Role of Blood-Brain Barrier Permeability, Plasma Protein Binding, and Brain Tissue Binding J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1254 - 1262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Doran, R. S. Obach, B. J. Smith, N. A. Hosea, S. Becker, E. Callegari, C. Chen, X. Chen, E. Choo, J. Cianfrogna, et al. THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL Drug Metab. Dispos., January 1, 2005; 33(1): 165 - 174. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
